| Species |
Human |
| Protein Construction |
CD24 (Ser27-Gly59)
Accession # P25063-1 |
mFc (IgG1) |
| N-term |
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Anti-CD24 Antibody at 2μg/ml (100μl/well) on the plate can bind CD24 mFc Chimera[Biotin], Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
29.5 kD |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 48-58 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers. |
| Synonyms |
CD 24; CD24 molecule; CD24A; FLJ22950; FLJ43543; MGC75043 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
